Molecular Partners AG (XSWX:MOLN)
CHF 3.305 -0.115 (-3.36%) Market Cap: 108.63 Mil Enterprise Value: -74.61 Mil PE Ratio: 0 PB Ratio: 0.62 GF Score: 53/100

Molecular Partners AG - Special Call Transcript

Jun 26, 2020 / NTS GMT
Release Date Price: CHF15.36 (-31.73%)
Operator

Ladies and gentlemen, welcome to the Molecular Partners conference call regarding the FDA decision of abicipar. I am Sandra, the Chorus Call operator. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Thomas Schneckenburger, Investor Relations. Please go ahead, sir.

Thomas Schneckenburger
Molecular Partners AG - VP of Finance, IR & Communications

Thanks, Sandra. Good morning, ladies and gentlemen. Welcome, everybody, to this conference call in relation to the joint news release which we have just published together with our partner, Allergan, regarding the FDA decision on the BLA for abicipar.

With me here in the room in Schlieren are: Patrick Amstutz, the CEO of Molecular Partners; Andreas Emmenegger, the Chief Financial Officer; and Michael Stumpp, the COO of the company. Moreover, on the phone, in the U.S., we have also Seth Lewis, our SVP, IR, Comms and Strategy. Patrick will start this call with a few opening remarks before we will move over to take your questions. Before starting, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot